Günther R. Adolf

Medicine · Health Sciences

30h-index4.2kcitations117works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(21), Melanoma and MAPK Pathways(21), Microtubule and mitosis dynamics(19), Colorectal Cancer Treatments and Studies(18), Cancer, Hypoxia, and Metabolism(14)

Publications117 total

Supplementary Table S4 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Supplementary Data Content from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Data from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Supplementary Figure 3 from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
2023Open Access
Supplementary Figure S4: Western blot analysis of MAPK pathway inhibition by BI 847325 in KRAS-mutant cell lines. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
2023Open Access
Supplementary Figure S2: Western blot analysis of MAPK pathway inhibition by BI 847325 in BRAF-mutant cell lines. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
2023Open Access
Supplementary Materials and Methods, Tables S1 through S3 and Figures S1 and S2 from BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis
2023Open Access
Supplementary Tables S1 and S2 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Data from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
2023Open Access
Supplementary Figure 1 from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
2023Open Access
Supplementary Information from The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy
2023Open Access
Supplementary Figure Legends from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Supplementary Table S4 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Supplementary Figure S3: Western blot analysis of MAPK pathway inhibition by BI 847325 in NRAS-mutant cell lines. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
2023Open Access
Supplementary Figure S1: Chemical structure of the AK-B inhibitor BI 811283. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
2023Open Access
Supplementary Tables S1 and S2 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Supplementary Figure 3 from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
2023Open Access
Data from The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy
2023Open Access
Supplementary Data Content from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
Supplementary Tables S5 and S6 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Pilar Garin‐Chesa(8), Norbert Kraut(7), Karl‐Heinz Heider(7), Ingrid Maurer-Fogy(7), Jens Quant(6), Anke Baum(5), Rudolf Hauptmann(4), Elínborg Ostermann(4), Herbert R. Lamche(4), Marco H. Hofmann(4), Erik Patzelt(4), Stephan K. Zahn(4), Ulrich Gürtler(3), Dorothea Rudolph(3), Christian Haslinger(3), Helmut Ponta(3), Peter Herrlich(3), Christoph Klade(3), Horst Ahorn(3), Adolf Himmler(3)